{"id":31460,"date":"2025-04-09T16:34:14","date_gmt":"2025-04-09T08:34:14","guid":{"rendered":"https:\/\/flcube.com\/?p=31460"},"modified":"2025-04-09T16:34:15","modified_gmt":"2025-04-09T08:34:15","slug":"bayer-submits-eylea-8-mg-for-rvo-macular-edema-approval-in-eu","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31460","title":{"rendered":"Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU"},"content":{"rendered":"\n

German pharmaceutical giant Bayer (ETR: BAYN<\/a>) announced that it has submitted an indication approval filing to the European Medicines Agency (EMA) for Eylea 8 mg (aflibercept 8 mg). The proposed indication is macular edema following retinal vein occlusion (RVO), including central, branch, and hemiretinal vein occlusion. This filing is supported by positive results from the Phase III QUASAR study, which demonstrated non-inferior visual acuity gains compared to the current standard therapy, Eylea 2 mg.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
In the QUASAR study, patients receiving aflibercept 8 mg every 8 weeks (after initial monthly doses) showed comparable visual acuity improvements to those receiving Eylea 2 mg every 4 weeks. Approximately 90% of patients on the 8 mg regimen maintained 8-week dosing intervals through 36 weeks, with nearly 70% extending to 12-week intervals. These results highlight the potential for extended dosing intervals, reducing treatment burden while maintaining efficacy.<\/p>\n\n\n\n

Regulatory and Market Context<\/strong>
Eylea, co-developed with Regeneron (NASDAQ: REGN<\/a>), has been approved for various ophthalmic indications since its FDA approval in November 2011. In the EU and UK, Eylea 8 mg is the only anti-VEGF therapy approved for extended treatment intervals of up to 5 months for nAMD and DME. In February 2025, Bayer filed to extend treatment intervals to 6 months for these conditions, leveraging data from the PULSAR and PHOTON studies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing…<\/p>\n","protected":false},"author":1,"featured_media":31461,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[269,967,38,1166,44,1426],"class_list":["post-31460","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-etr-bayn","tag-market-approval-filings","tag-nasdaq-regn","tag-ophthalmology","tag-regeneron-pharmaceuticals"],"yoast_head":"\nBayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing to the European Medicines Agency (EMA) for Eylea 8 mg (aflibercept 8 mg). The proposed indication is macular edema following retinal vein occlusion (RVO), including central, branch, and hemiretinal vein occlusion. This filing is supported by positive results from the Phase III QUASAR study, which demonstrated non-inferior visual acuity gains compared to the current standard therapy, Eylea 2 mg.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31460\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU\" \/>\n<meta property=\"og:description\" content=\"German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing to the European Medicines Agency (EMA) for Eylea 8 mg (aflibercept 8 mg). The proposed indication is macular edema following retinal vein occlusion (RVO), including central, branch, and hemiretinal vein occlusion. This filing is supported by positive results from the Phase III QUASAR study, which demonstrated non-inferior visual acuity gains compared to the current standard therapy, Eylea 2 mg.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31460\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T08:34:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-09T08:34:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0910-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31460#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31460\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU\",\"datePublished\":\"2025-04-09T08:34:14+00:00\",\"dateModified\":\"2025-04-09T08:34:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31460\"},\"wordCount\":218,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31460#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0910-png.webp\",\"keywords\":[\"Bayer\",\"ETR: BAYN\",\"Market approval filings\",\"NASDAQ: REGN\",\"Ophthalmology\",\"Regeneron Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31460#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31460\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31460\",\"name\":\"Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31460#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31460#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0910-png.webp\",\"datePublished\":\"2025-04-09T08:34:14+00:00\",\"dateModified\":\"2025-04-09T08:34:15+00:00\",\"description\":\"German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing to the European Medicines Agency (EMA) for Eylea 8 mg (aflibercept 8 mg). The proposed indication is macular edema following retinal vein occlusion (RVO), including central, branch, and hemiretinal vein occlusion. This filing is supported by positive results from the Phase III QUASAR study, which demonstrated non-inferior visual acuity gains compared to the current standard therapy, Eylea 2 mg.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31460#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31460\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31460#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0910-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0910-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31460#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU - Insight, China's Pharmaceutical Industry","description":"German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing to the European Medicines Agency (EMA) for Eylea 8 mg (aflibercept 8 mg). The proposed indication is macular edema following retinal vein occlusion (RVO), including central, branch, and hemiretinal vein occlusion. This filing is supported by positive results from the Phase III QUASAR study, which demonstrated non-inferior visual acuity gains compared to the current standard therapy, Eylea 2 mg.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31460","og_locale":"en_US","og_type":"article","og_title":"Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU","og_description":"German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing to the European Medicines Agency (EMA) for Eylea 8 mg (aflibercept 8 mg). The proposed indication is macular edema following retinal vein occlusion (RVO), including central, branch, and hemiretinal vein occlusion. This filing is supported by positive results from the Phase III QUASAR study, which demonstrated non-inferior visual acuity gains compared to the current standard therapy, Eylea 2 mg.","og_url":"https:\/\/flcube.com\/?p=31460","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-09T08:34:14+00:00","article_modified_time":"2025-04-09T08:34:15+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0910-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31460#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31460"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU","datePublished":"2025-04-09T08:34:14+00:00","dateModified":"2025-04-09T08:34:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31460"},"wordCount":218,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31460#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0910-png.webp","keywords":["Bayer","ETR: BAYN","Market approval filings","NASDAQ: REGN","Ophthalmology","Regeneron Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31460#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31460","url":"https:\/\/flcube.com\/?p=31460","name":"Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31460#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31460#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0910-png.webp","datePublished":"2025-04-09T08:34:14+00:00","dateModified":"2025-04-09T08:34:15+00:00","description":"German pharmaceutical giant Bayer (ETR: BAYN) announced that it has submitted an indication approval filing to the European Medicines Agency (EMA) for Eylea 8 mg (aflibercept 8 mg). The proposed indication is macular edema following retinal vein occlusion (RVO), including central, branch, and hemiretinal vein occlusion. This filing is supported by positive results from the Phase III QUASAR study, which demonstrated non-inferior visual acuity gains compared to the current standard therapy, Eylea 2 mg.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31460#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31460"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31460#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0910-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0910-png.webp","width":1080,"height":608,"caption":"Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31460#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer Submits Eylea 8 mg for RVO Macular Edema Approval in EU"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0910-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31460"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31460\/revisions"}],"predecessor-version":[{"id":31462,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31460\/revisions\/31462"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31461"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}